Remove 2027 Remove Drug Pricing Remove Packaging
article thumbnail

STAT+: Key House panel proposes lowering out-of-pocket drug costs in Medicare

STAT

The House Ways & Means Committee package includes a new provision that would ensure that patients in the Medicare program pay for medicines they pick up at the pharmacy counter based on the discounted price that insurers negotiate with drugmakers, instead of higher sticker prices, starting in 2027.

Packaging 246
article thumbnail

STAT+: Pharmalittle: Biogen to slash 1,000 more jobs; key House panel proposes lowering Medicare out-of-pocket drug costs

STAT

The company had said in April it would pause or discontinue at least four studies of experimental drugs to focus on more lucrative options including the Leqembi launch and trim costs. This protection has not been proposed in any other legislation considered by health care committees in Congress.

Packaging 246
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Merck concludes SpringWorks acquisition for $3.4bn

Pharmaceutical Technology

The merger, announced in April 2025 , will positively impact Merck’s financial position by contributing to revenues immediately, and is anticipated to be accretive to its earnings per share by 2027. How will RFK Jr’s American dream for vaccines play out? Give your business an edge with our leading industry insights.

article thumbnail

Sanofi agrees to invest $25m in Adagene

Pharmaceutical Technology

With the additional funds from Sanofi’s investment and current assets on hand, it anticipates sufficient funds to sustain its planned operations in 2027. How will RFK Jr’s American dream for vaccines play out? As of December 2024, the company reported cash reserves of $85.2m.

article thumbnail

FDA approves Takeda’s Gammagard liquid ERC for primary immunodeficiency

Pharmaceutical Technology

Takeda anticipates commencing commercialisation efforts for Gammagard liquid ERC in the US by 2026, with plans to follow suit in the European Union (EU) by 2027. How will RFK Jr’s American dream for vaccines play out? GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate?

article thumbnail

Piramal Pharma announces $90m investment to expand US sites

Pharmaceutical Technology

The expansion will be concluded by late 2027, with production capacity increasing from 104 batches annually at peak utilisation to more than 240 batches. How will RFK Jr’s American dream for vaccines play out? Give your business an edge with our leading industry insights.